InfuSystems Holdings Inc (INFU)vsNovartis AG ADR (NVS)
INFU
InfuSystems Holdings Inc
$10.13
+3.05%
HEALTHCARE · Cap: $215.27M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 39345% more annual revenue ($56.58B vs $143.44M). NVS leads profitability with a 23.9% profit margin vs 4.6%. INFU appears more attractively valued with a PEG of 1.73. INFU earns a higher WallStSmart Score of 53/100 (C-).
INFU
Buy53
out of 100
Grade: C-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.4%
Fair Value
$15.03
Current Price
$10.13
$4.90 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 123.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
4.6% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INFU
The strongest argument for INFU centers on EPS Growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : INFU
The primary concerns for INFU are PEG Ratio, P/E Ratio, Market Cap. Thin 4.6% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
INFU profiles as a value stock while NVS is a declining play — different risk/reward profiles.
INFU carries more volatility with a beta of 1.55 — expect wider price swings.
INFU is growing revenue faster at 7.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
INFU scores higher overall (53/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InfuSystems Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?